

Cover image: Proliferation of synovial cells and inflammatory cell infiltration in the joints of recipient mice injected with heat-aggregated ovalbumin plus lipopolysaccharide. See p1059.

### Editor

Tore K Kvien

### Associate Editors

Francis Berenbaum  
Hans Bijlsma  
Dimitrios Boumpas  
Gerd Burmester  
Mary Crow  
Iain McInnes

### Editorial office

Annals of the Rheumatic Diseases  
BMJ Publishing Group Ltd  
BMA House  
Tavistock Square  
London WC1H 9JR, UK  
T: +44 (0)20 7383 6250  
F: +44 (0)20 7383 6668  
E: [ard@bmj.com](mailto:ard@bmj.com)  
ISSN: 0003-4967 (print)  
ISSN: 1468-2060 (online)  
Impact Factor: 6.411

**Disclaimer:** ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions, the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

**Copyright:** © 2009 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior permission. ARD is published by BMJ Publishing Group Ltd, typeset by The Charlesworth Group and printed in the UK on acid-free paper from sustainable forests by Cambrian Printers Limited, Aberystwyth, UK.

*Annals of the Rheumatic Diseases* (USPS No: 002-152) is published monthly by BMJ Publishing Group and distributed in the USA by SPP, 75 Aberdeen Road, Emigsville, PA 17318, USA. Periodicals postage paid at Emigsville, PA, USA. POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, PO Box 437, Emigsville, PA 17318-0437, USA.

## Editorials

**765** Diagnosing axial spondyloarthritis. The new Assessment in SpondyloArthritis international Society criteria: MRI entering centre stage  
*A N Bennett, H Marzo-Ortega, P Emery, D McGonagle, on behalf of the Leeds Spondyloarthritis Group*

**767** New tumour necrosis factor inhibitors for rheumatoid arthritis: are there benefits from extending choice?  
*D L Scott, A Cope*

## Clinical and epidemiological research

**770** The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal  
*M Rudwaleit, R Landewé, D van der Heijde, J Listing, J Brandt, J Braun, R Burgos-Vargas, E Collantes-Estevez, J Davis, B Dijkemans, M Dougados, P Emery, I E van der Horst-Bruinsma, R Inman, M A Khan, M Leirisalo-Repo, S van der Linden, W P Maksymowych, H Mielants, I Olivieri, R Sturrock, K de Vlam, J Sieper*

**777** The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection  
*M Rudwaleit, D van der Heijde, R Landewé, J Listing, N Akkoc, J Brandt, J Braun, C T Chou, E Collantes-Estevez, M Dougados, F Huang, J Gu, M A Khan, Y Kirazli, W P Maksymowych, H Mielants, I J Sørensen, S Ozgocmen, E Roussou, R Valle-Oñate, U Weber, J Wei, J Sieper*

**784** New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS)  
*J Sieper, D van der Heijde, R Landewé, J Brandt, R Burgos-Vargas, E Collantes-Estevez, B Dijkemans, M Dougados, M A Khan, M Leirisalo-Repo, S van der Linden, W P Maksymowych, H Mielants, I Olivieri, M Rudwaleit*

**789** Golimumab, a human antibody to tumour necrosis factor  $\alpha$  given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study  
*E C Keystone, M C Genovese, L Klareskog, E C Hsia, S T Hall, P C Miranda, J Pazdur, S-C Bae, W Palmer, J Zrubeck, M Wiekowski, S Visvanathan, Z Wu, M U Rahman*

**797** Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial  
*J Smolen, R B Landewé, P Mease, J Brzezicki, D Mason, K Luijckens, R F van Vollenhoven, A Kavanaugh, M Schiff, G R Burmester, V Strand, J Vencovsky, D van der Heijde*

**805** Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study  
*R Fleischmann, J Vencovsky, R F van Vollenhoven, D Borenstein, J Box, G Coteur, N Goel, H-P Brezinschek, A Innes, V Strand*

**812** Impaired memory and learning abilities in patients with systemic lupus erythematosus as measured by the Rey Auditory Verbal Learning Test  
*D Paran, I Litinsky, I Shapira-Lichter, S Navon, T Hendler, D Caspi, E Vakil*

**817** Vitamin D and chronic widespread pain in a white middle-aged British population: evidence from a cross-sectional population survey  
*K Atherton, D J Berry, T Parsons, G J Macfarlane, C Power, E Hyppönen*

**823** Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade  
*J S Smolen, C Han, D M F M van der Heijde, P Emery, J M Bathon, E Keystone, R N Maini, J R Kalden, D Aletaha, D Baker, J Han, M Bala, E W St Clair, for the Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group*

**828** Disease progression in mothers of children enrolled in the Research Registry for Neonatal Lupus  
*T L Rivera, P M Izmirly, B K Birnbaum, P Byrne, J B Brauth, M Katholi, M Y Kim, J Fischer, R M Clancy, J P Buyon*

**836** Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies  
*O Kryšůřková, T Vallerskog, S Barbasso Helmers, H Mann, I Půtová, J Běláček, V Malmström, C Trollmo, J Vencovsky, I E Lundberg*

### MORE CONTENTS ►



This article has been chosen by the editor to be of special interest or importance and is freely available online.



Articles carrying the Unlocked Logo are freely available online under the BMJ Journals unlocked scheme. See <http://ard.bmj.com/info/unlocked.dtl>

C O P E COMMITTEE ON PUBLICATION ETHICS



This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

[www.publicationethics.org.uk](http://www.publicationethics.org.uk)

equator network

recycle  
When you have finished with this please recycle it

- 844** Evaluating guidelines on continuation of anti-tumour necrosis factor treatment after 3 months: clinical effectiveness and costs of observed care and different alternative strategies  
*W Kievit, J Fransen, E M Adang, H H Kuper, T L Jansen, C M A De Gendt, D J R A M De Rooij, H L M Brus, M A F J van de Laar, P C L M Van Riel*
- 850** Bone marrow lesions predict increase in knee cartilage defects and loss of cartilage volume in middle-aged women without knee pain over 2 years  
*A E Wluka, F Hanna, M Davies-Tuck, Y Wang, R J Bell, S R Davis, J Adams, F M Cicuttini*
- 856** Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (EUSTAR) group database  
*U A Walker, A Tyndall, L Czirják, C P Denton, D Farge-Bancel, O Kowal-Bielecka, U Müller-Ladner, M Matucci-Cerinic, and the EUSTAR co-authors*
- 863** Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine  
*R Landewé, M Dougados, H Mielants, H van der Tempel, D van der Heijde*
- 868** Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients  
*C Popa, L J H van Tits, P Barrera, H L M Lemmers, F H J van den Hoogen, P L C M van Riel, T R D J Radstake, M G Netea, M Roest, A F H Stalenhoef*
- 873** Wegener's granulomatosis patients show an adequate antibody response to influenza vaccination  
*A Holvast, C A Stegeman, C A Benne, A Huckriede, J C Wilschut, A M Palache, C G M Kallenberg, M Bijl*
- 879** Responsiveness of the International Classification of Functioning, Disability and Health (ICF) Core Set for rheumatoid arthritis  
*T Uhlig, R Moe, S Reinsberg, T K Kvien, A Cieza, G Stucki*
- 885** Evaluation of work-related psychosocial factors and regional musculoskeletal pain: results from a EULAR Task Force  
*G J Macfarlane, N Pallewatte, P Paudyal, F M Blyth, D Coggon, G Crombez, S Linton, P Leino-Arjas, A J Silman, R J Smeets, D van der Windt*
- 892** A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with gout  
*M K Reinders, C Haagsma, T L Th A Jansen, E N van Roon, J Delsing, M A F J van de Laar, J R B J Brouwers*
- 898** Influence of peptidylarginine deiminase type 4 genotype and shared epitope on clinical characteristics and autoantibody profile of rheumatoid arthritis  
*B Hoppe, T Häupl, K Egerer, R Gruber, H Kiesewetter, A Salama, G R Burmester, T Dörner*
- 904** The natural history of bone marrow lesions in community-based adults with no clinical knee osteoarthritis  
*M L Davies-Tuck, A E Wluka, Y Wang, D R English, G G Giles, F Cicuttini*
- 909** Obesity and adiposity are associated with the rate of patella cartilage volume loss over 2 years in adults without knee osteoarthritis  
*A J Teichtahl, A E Wluka, Y Wang, F Hanna, D R English, G G Giles, F M Cicuttini*
- 914** Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis  
*S M van der Kooij, Y P M Goekoop-Ruiterman, J K de Vries-Bouwstra, M Güler-Yüksel, A H Zwinderman, P J S M Kerstens, P A H M van der Lubbe, W M de Beus, B A M Grillet, H K Runday, T W J Huizinga, F C Breedveld, B A C Dijkmans, C F Allaart*
- 922** Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial  
*D van der Heijde, M H Schiff, J Sieper, A J Kivitz, R L Wong, H Kupper, B A C Dijkmans, P J Mease, J C Davis Jr, for the ATLAS Study Group*
- 930** Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group  
*M T Halpern, M A Cifaldi, T K Kvien*
- 938** Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI  
*J-P Raynaud, J Martel-Pelletier, P Bias, S Laufer, B Haraoui, D Choquette, A D Beaulieu, F Abram, M Dorais, É Vignon, J-P Pelletier, and the Canadian Licofelone Study Group*
- 948** Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index  
*W P Maksymowych, C Mallon, S Morrow, K Shojania, W P Olszynski, R L Wong, J Sampalis, B Conner-Spady*
- 954** Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate  
*G Wells, J-C Becker, J Teng, M Dougados, M Schiff, J Smolen, D Aletaha, P L C M van Riel*

- 961** Systemic sclerosis and its pulmonary complications in The Netherlands: an epidemiological study  
*M C Vonk, B Broers, Y F Heijdra, E Ton, R Snijder, A P J van Dijk, J M van Laar, H Bootsma, P Th W van Hal, F H J van den Hoogen, P L A van Daele*
- 966** Thoracoabdominal motion in ankylosing spondylitis: association with standardised clinical measures and response to therapy  
*G E Tzelepis, G Kalliakosta, A G Tzioufas, P P Sfikakis, C Mandros, K A Boki, C Roussos, H M Moutsopoulos*
- 972** Test–retest reliability of disease activity core set measures and indices in rheumatoid arthritis  
*T Uhlig, T K Kvien, T Pincus*
- 
- Basic and translational research**
- 976** Hsp90 $\beta$  and p130<sup>cas</sup>: novel regulatory factors of MMP-13 expression in human osteoarthritic chondrocytes  
*Z Fan, G Tardif, D Hum, N Duval, J-P Pelletier, J Martel-Pelletier*
- 983** Thymic function in juvenile idiopathic arthritis  
 *A R Lorenzi, T A Morgan, A Anderson, J Catterall, A M Patterson, H E Foster, J D Isaacs*
- 991** Severe alterations in expression and localisation of  $\alpha 6\beta 4$  integrin in salivary gland acini from patients with Sjögren syndrome  
*J Velozo, S Aguilera, C Allende, P Ewert, C Molina, P Pérez, L Leyton, A Quest, M Brito, S González, C Leyton, M Hermoso, R Romo, M-J González*
- 997** Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus  
*J Morel, C Roubille, L Planelles, C Rocha, L Fernandez, C Lukas, M Hahne, B Combe*
- 1003** Evidence for a distinctive pattern of bone formation in enthesophytes  
*M Benjamin, H Toumi, D Suzuki, K Hayashi, D McGonagle*
- 1011** Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation  
*Y K O Teng, E W N Levarht, R E M Toes, T W J Huizinga, J M van Laar*
- 1017** Testing the druggable endothelial differentiation gene 2 knee osteoarthritis genetic factor for replication in a wide range of sample collections  
*R Diegues-Gonzalez, M Calaza, D Shi, I Meulenbelt, J Loughlin, A Tsezou, J Dai, K N Malizos, E P Slagboom, M Kloppenburg, K Chapman, Q Jiang, D Kremer, J J Gomez-Reino, N Nakajima, S Ikegawa, A Gonzalez*
- 1022** Exposure to nuclear antigens contributes to the induction of humoral autoimmunity during tumour necrosis factor alpha blockade  
*T Cantaert, L De Rycke, C P Mavragani, C A Wijbrandts, T B Niewold, T Niers, B Vandooren, E M Veys, D Richel, P P Tak, M K Crow, D Baeten*
- 1030** Complement activation in patients with primary antiphospholipid syndrome  
*K Oku, T Atsumi, M Bohgaki, O Amengual, H Kataoka, T Horita, S Yasuda, T Koike*
- 1036** Regulation of CXCL16 expression and secretion by myeloid cells is not altered in rheumatoid arthritis  
*A W T van Lieshout, R van der Voort, L W J Toonen, S F G van Helden, C G Figdor, P L C M van Riel, T R D J Radsstake, G J Adema*
- 1044** Melanoma inhibitory activity, a biomarker related to chondrocyte anabolism, is reversibly suppressed by proinflammatory cytokines in rheumatoid arthritis  
*B Vandooren, T Cantaert, M-J van Lierop, E Bos, L De Rycke, E M Veys, F De Keyser, B Bresnihan, F P Luyten, P C Verdonk, P P Tak, A H Boots, D Baeten*
- 1051** Hyaluronan inhibits expression of ADAMTS4 (aggrecanase-1) in human osteoarthritic chondrocytes  
 *T Yatabe, S Mochizuki, M Takizawa, M Chijiwa, A Okada, T Kimura, Y Fujita, H Matsumoto, Y Toyama, Y Okada*
- 1059** Dissecting the contribution of innate and antigen-specific pathways to the breach of self-tolerance observed in a murine model of arthritis  
*M B Nickdel, P Conigliaro, G Valesini, S Hutchison, R Benson, R V Bundick, A J Leishman, I B McInnes, J M Brewer, P Garside*
- 1067** Severe impaired respiratory ciliary function in Wegener granulomatosis  
*S Ullrich, H Gustke, P Lamprecht, W L Gross, U Schumacher, P Ambrosch, M Laudien*
- 
- Letters**
- 1072** Tendency towards erosive regression on magnetic resonance imaging at 12 months in rheumatoid arthritis patients treated with rituximab  
*U Møller Døhn, M Østergaard, P Bird, A Boonen, J S Johansen, J M Møller, M S Hansen*
- 1074** Diagnostic value of procalcitonin for differentiation between bacterial infection and non-infectious inflammation in febrile patients with active adult-onset Still's disease  
*D-Y Chen, Y-M Chen, W-L Ho, H-H Chen, G-H Shen, J-L Lan*
- 1075** Rituximab fixed retreatment versus on-demand retreatment in refractory rheumatoid arthritis: comparison of two B cell depleting treatment strategies  
*Y K O Teng, J Tekstra, F C Breedveld, F Laféber, J W J Bijlsma, J M van Laar*
- 1077** Refractory severe connective tissue disease thrombocytopenia: is rituximab treatment effective and safe?  
*W J Zheng, X Zhang, Q Wang, D Xu, X F Zeng, F C Zhang*
- 1078** Erosive osteoarthritis of the hand: clinical experience with anakinra  
*L Bacconnier, C Jorgensen, S Fabre*
- 
- Miscellaneous**
- 1080** Corrections